Floatz Rating
CCC50/100
Confidence
Indicative
Sponsor
University of British Columbia
Modality
Small molecule
Development Phase
Phase 2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
35Moderate confidence
Detailed axis rationale is planned and will be published soon.
No trial-level evidence is linked to this axis yet.
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Childhood Absence Epilepsy
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Flunarizine Hcl (this asset) | University of British Columbia | P2 | CCC · 50 |
| Lamotrigine | Children's Hospital Medical Center, Cincinnati | P3 | BB |
| Ethosuximide | Children's Hospital Medical Center, Cincinnati | P3 | BB |
| Brivaracetam | UCB Biopharma SRL | P3 | B |
| Brivaracetam Film-Coated | UCB Biopharma SRL | P3 | B |
| Valproic Acid | Children's Hospital Medical Center, Cincinnati | P3 | B |
| Topiramate | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | P2 | B |
| Npt 2042 | NeuroPro Therapeutics, Inc. | P2 | CCC |
| Bmb-101 | Bright Minds Biosciences Pty Ltd | P2 | NR |
Other indications for Flunarizine Hcl
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Juvenile Absence Epilepsy | — | P2 | CCC · 50 |
| Juvenile Myoclonic Epilepsy | — | P2 | CCC · 50 |
| Migraine Without Aura | — | P1 | CC · 43 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Flunarizine Hcl in Childhood Absence Epilepsy. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/flunarizine-hcl-childhood-absence-epilepsy
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →